Elicio Therapeutics (ELTX) Stock Analysis: AI Score & Alternative Data
Alt-data signals are cooling for Elicio Therapeutics
Is Elicio Therapeutics a buy right now? The alternative data leans no. This ELTX stock analysis is built on the 25+ alternative data signals AltIndex tracks on Elicio Therapeutics every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 36/100: a Sell. The stock trades at $1.85 with a $49M market cap.
The 90-day pressure points: web traffic down 7.1% to 8K monthly visits, and just 27% of employees report a positive business outlook. Stocks scoring below 40 have historically lagged the market.
ELTX’s broader alt-data profile also covers headcount (47 employees, according to LinkedIn), X followers (444), and sentiment (95/100). Every signal links to its own page with full history, the ELTX technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on ELTX is just below.
Elicio Therapeutics AI Stock Analysis
Elicio Therapeutics is a biopharmaceutical company focused on pioneering the development of transformative immunotherapeutics for patients suffering from cancer and rare diseases. The company leverages its proprietary Amphiphile technology to engineer potent drugs designed to harness the sophistication of the immune system.
Analysis generated October 4, 2026.
Recent Elicio Therapeutics Stock Alerts
|
Elicio Therapeutics | October 1 Price is up by 6% in the last 24h. |
|
Elicio Therapeutics | September 21 Price is up by 6.4% in the last 24h. |
|
Elicio Therapeutics | September 9 Price is down by -6.4% in the last 24h. |
|
Elicio Therapeutics | August 19 Price is up by 6.1% in the last 24h. |
Elicio Therapeutics Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 8K | 7.1% | |
| Job Posts | 0 | N/A | |
| LinkedIn Employees | 47 | 2.2% | |
| Employee Recommend | 27 | 0% | |
| Business Outlook | 27 | 0% | |
| Sentiment | 95 | 0% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 1 | 50.0% | |
| Stocktwits Mentions | 2 | 94.7% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 781 | 9.0% | |
| 4chan Mentions | 0 | N/A | |
| X Followers | 444 | 1.4% |
About Elicio Therapeutics (ELTX)
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.
| Price | $1.85 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $49M |
| Year Range | $2 – $15 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Elicio Therapeutics News
View more → |
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTXJuly 9 - PRNewswire |
Elicio Therapeutics Announces Closing of $15 Million Registered Direct OfferingJuly 6 - GlobeNewswire |
|
 |
Elicio Therapeutics drops 5%, prices $15M registered direct offeringJuly 1 - Seeking Alpha |
|
Elicio Therapeutics drops 5%, prices $15M direct offeringJuly 1 - Seeking Alpha |
See Elicio Therapeutics’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for ELTX, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEElicio Therapeutics Earnings & Financial Performance
View all earnings →Elicio Therapeutics Insider Trading Activity
View all →| GKCC, LLC filed to sell 3,442,341 shares at $0.0. Aug 12 '24 |
| Venkatesan Jay filed to sell 50,000 shares at $0.0. Jun 28 '24 |
| Venkatesan Jay filed to sell 50,000 shares at $0.0. Jun 28 '24 |
| GKCC, LLC filed to sell 1,600,000 shares at $0.0. Jun 28 '24 |
| GKCC, LLC filed to sell 1,032,702 shares at $0.0. Mar 19 '24 |
Elicio Therapeutics Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Elicio Therapeutics
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
eXoZymes Inc. - Common StockEXOZ |
$5.54 0.4% | $51M | 50 |
 |
Serina TherapeuticsSER |
$2.01 1.5% | $52M | 47 |
 |
INmune BioINMB |
$1.86 0.5% | $52M | 45 |
 |
NovaBay PharmaceuticalsNBY |
$1.95 22.6% | $52M | 40 |
 |
Kezar Life SciencesKZR |
$7.29 1.0% | $54M | 44 |
Explore Elicio Therapeutics Data
Frequently Asked Questions: Elicio Therapeutics (ELTX)
Elicio Therapeutics has an AltIndex AI Score of 36/100 (Sell). The score reflects negative alternative data signals. All investments carry risk.
36/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Elicio Therapeutics (ELTX) stock is $1.85 with a market cap of $49M.
As of today, Elicio Therapeutics’s PE (Price to Earnings) ratio is —.
View the latest Elicio Therapeutics insider transactions to see recent buying and selling activity by company executives and directors.
Check the Elicio Therapeutics congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The ELTX stock price chart above shows Elicio Therapeutics’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Elicio Therapeutics technical analysis for RSI, moving averages, and more.
See the stocks similar to Elicio Therapeutics section on this page for companies in the same industry ranked by market cap and AI Score.
